CORRELATION OF TUMOR MARKERS HER2 NEU ER PR AND KI 67 IN BREAST CANCER PATIENTS

MN RASHID; NU HUDA; L RIAZ; RA SHAHID; AM SIDDIQUI; F BUTT

doi:10.54112/bcsrj.v2024i1.793

Authors

MN RASHID Department of Physiology/ Medical Education, Research and Ethics Department, Shaheed Mohtarma Benazir Bhutto Medical College, Dow University of Health Sciences, Karachi, Pakistan
NU HUDA Department of Anatomy, Dow University of Health Sciences Karachi, Pakistan
L RIAZ Department of Forensic Medicine, Dow University of Health Sciences Karachi, Pakistan
RA SHAHID Department of Physiology, DDC, Dow University of Health Sciences Karachi, Pakistan
AM SIDDIQUI Department of Anatomy, Dow University of Health Sciences Karachi, Pakistan
F BUTT Department of Physiology, Dow University of Health Sciences, Karachi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.793

Keywords:

Breast Cancer, Estrogen Receptor, HER2, KI67, Progesterone Receptor

Abstract

: Every year, more than a million women are diagnosed with breast cancer, and over 700.000 of them have positive for hormone receptors (FIR). The expression of key markers, such as ER and PP, and clinical circumstances show specific biological traits. Risk factors may have a role in the development of some hormone receptor-positive breast cancers. Objective: The objective of this study was to investigate the correlations between key tumor markers, including HER2, ER, PR, ALP, and KI67, in hormone receptor-positive breast cancers. Methods: Tumour tissue samples were collected for histopathology (10% neutral buffered Formalin-fixed paraffin-embedded tissue specimens) during Trucut biopsy or mastectomy at the oncology department of a tertiary care hospital in Karachi from October 2022 to July 2023. Tissues were analyzed under a light microscope for tumor hormone receptors at a tertiary care hospital in Karachi. Results: There were several significant correlations observed between HER 2 NUE, KI 67, ER, and PR. Specifically, a weak negative correlation was noted between HER 2 NUE and KI 67, while weak positive correlations were observed between HER 2 NUE and both ER and PR. Additionally, a weak positive correlation was found between ER and HER 2 NUE, PR, and KI 67, and a weak positive correlation existed between PR and ER, HER 2 NUE, and KI 67. Finally, KI 67 displayed a weak positive correlation with HER 2 NUE, PR, and ER. Conclusions: Her two nurses, ER, ALP, KI 67, and breastfeeding, are significantly and directly related. PR is not significantly related to other mentioned tumor markers.

Downloads

Download data is not yet available.

References

Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. The British journal of radiology. 2022;95(1130):20211033.

Britt KL, Cuzick J, Phillips K-A. Key steps for effective breast cancer prevention. Nature Reviews Cancer. 2020;20(8):417-36.

Milosevic M, Jankovic D, Milenkovic A, Stojanov D. Early breast cancer diagnosis and detection. Technology and Health Care. 2018;26(4):729-59.

Pirsaheb M, Mohammadi S, Salimi A. Current advances of carbon dots based biosensors for tumour marker detection, cancer cells analysis and bioimaging. TrAC Trends in Analytical Chemistry. 2019;115:83-99.

Hong R, Sun H, Li D, Yang W, Fan K, Liu C, et al. A review of biosensors for detecting tumor markers in breast cancer. Life. 2022;12(3):342.

Mutebi M, Unger-Saldaña K, Ginsburg O. Breast cancer: Burden, epidemiology and priority interventions. Noncommunicable Diseases. 2023:91-7.

Duffy M, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). European journal of cancer. 2017;75:284-98.

Begam AJ, Jubie S, Nanjan M. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorganic chemistry. 2017;71:257-74.

Martinez-Perez C, Turnbull AK, Dixon JM. The evolving role of receptors as predictive biomarkers for metastatic breast cancer. Expert Review of Anticancer Therapy. 2019;19(2):121-38.

Reinert T, Cascelli F, Resende CAAd, Goncalves AC, Godo VSP. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer. Frontiers in Endocrinology. 2022;13:1015388.

Trabert B, Sherman ME, Kannan N, Stanczyk FZ. Progesterone and breast cancer. Endocrine reviews. 2020;41(2):320-44.

Honma N, Matsuda Y, Mikami T. Carcinogenesis of triple-negative breast cancer and sex steroid hormones. Cancers. 2021;13(11):2588.

Woo ARE, Sze SK, Chung HH, Lin VC. Delineation of critical amino acids in activation function 1 of progesterone receptor for recruitment of transcription coregulators. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2019;1862(4):522-33.

Fasching PA, Gass P, Häberle L, Volz B, Hein A, Hack CC, et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast cancer research and treatment. 2019;175:617-25.

Finn RS, Liu Y, Zhu Z, Martin M, Rugo HS, Diéras V, et al. Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer. Clinical Cancer Research. 2020;26(1):110-21.

De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, et al. Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer. Clinical Cancer Research. 2021;27(17):4870-82.

Dodson A. Measuring Ki-67 in Breast Cancer: Past, Present, and Future. Artificial Intelligence Applications in Human Pathology2022. p. 71-98.

Bienz M, Ramdani S, Knecht H. Molecular pathogenesis of Hodgkin lymphoma: past, present, future. International Journal of Molecular Sciences. 2020;21(18):6623.

Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018;127:175-86.

Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clinica chimica acta. 2019;491:39-45.

Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer biology & medicine. 2016;13(4):496.

Alco G, Bozdogan A, Selamoglu D, Pilancı KN, Tuzlalı S, Ordu C, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncology letters. 2015;9(3):1046-54.

Kilickap S, Kaya Y, Yücel B, Tuncer E, AKGÜL BABACAN N, Elagoz S. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pacific Journal of Cancer Prevention. 2014;15(3).

Al Nemer A. The performance of Ki-67 labeling index in different specimen categories of invasive ductal carcinoma of the breast using 2 scoring methods. Applied Immunohistochemistry & Molecular Morphology. 2017;25(2):86-90.